These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 30880227)

  • 21. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
    Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
    Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
    PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections: are carbapenem alternatives achievable in daily practice?
    Pilmis B; Delory T; Groh M; Weiss E; Emirian A; Lecuyer H; Lesprit P; Zahar JR
    Int J Infect Dis; 2015 Oct; 39():62-7. PubMed ID: 26327124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].
    Xiong Z; Zhu D; Zhang Y; Wang F
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1476-9. PubMed ID: 12509910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intervention study of the association of antibiotic utilization measures with control of extended-spectrum beta-lactamase (ESBL)-producing bacteria.
    Wen Z; Wei X; Xiao Y; Xue F; Hao F; Zhu Y; Ma N; Xiao Y; Wang H
    Microbes Infect; 2010 Sep; 12(10):710-5. PubMed ID: 20457272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen).
    Bitterman R; Koppel F; Mussini C; Geffen Y; Chowers M; Rahav G; Nesher L; Ben-Ami R; Turjeman A; Huberman Samuel M; Cheng MP; Lee TC; Leibovici L; Yahav D; Paul M
    BMJ Open; 2021 Feb; 11(2):e040210. PubMed ID: 33558347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
    Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
    Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of flomoxef against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Korea.
    Jung Y; Lee SS; Song W; Kim HS; Uh Y
    Diagn Microbiol Infect Dis; 2019 May; 94(1):88-92. PubMed ID: 30658867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum β-lactamase.
    Morfín-Otero R; Mendoza-Olazarán S; Silva-Sánchez J; Rodríguez-Noriega E; Laca-Díaz J; Tinoco-Carrillo P; Petersen L; López P; Reyna-Flores F; Alcantar-Curiel D; Garza-Ramos U; Garza-González E
    Microb Drug Resist; 2013 Oct; 19(5):378-83. PubMed ID: 23725513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pediatric extended spectrum β-lactamase infection: Community-acquired infection and treatment options.
    Sethaphanich N; Santanirand P; Rattanasiri S; Techasaensiri C; Chaisavaneeyakorn S; Apiwattanakul N
    Pediatr Int; 2016 May; 58(5):338-46. PubMed ID: 26513341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasmid-mediated quinolone resistance among extended spectrum beta lactase producing Enterobacteriaceae from bloodstream infections.
    Domokos J; Kristóf K; Szabó D
    Acta Microbiol Immunol Hung; 2016 Sep; 63(3):313-323. PubMed ID: 27539331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended-spectrum beta-lactamase (ESBL) CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae in Sofia, Bulgaria.
    Markovska R; Schneider I; Keuleyan E; Bauernfeind A
    Clin Microbiol Infect; 2004 Aug; 10(8):752-5. PubMed ID: 15301679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Susceptibility of ESBL-producing Escherichia coli and Klebsiella pneumoniae to various antibacterial agents].
    Nakamura T; Komatsu M
    Jpn J Antibiot; 2005 Feb; 58(1):1-10. PubMed ID: 15847220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended spectrum beta-lactamase and metallo beta-lactamase production among Escherichia coli and Klebsiella pneumoniae isolated from different clinical samples in a tertiary care hospital in Kathmandu, Nepal.
    Nepal K; Pant ND; Neupane B; Belbase A; Baidhya R; Shrestha RK; Lekhak B; Bhatta DR; Jha B
    Ann Clin Microbiol Antimicrob; 2017 Sep; 16(1):62. PubMed ID: 28927454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Extended-spectrum beta-lactamase detection in Enterobacteriaceae and antibiotic susceptibility analysis].
    Cao W; Tong MH; Wang JG
    Hunan Yi Ke Da Xue Xue Bao; 2002 Feb; 27(1):77-8. PubMed ID: 12575246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Epidemiological study on extended-spectrum beta-lactamase-producing in clinical isolates and selection of antibacterial drugs in China ].
    Yu YS
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1918-20. PubMed ID: 15631810
    [No Abstract]   [Full Text] [Related]  

  • 38. Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
    Sheu CC; Lin SY; Chang YT; Lee CY; Chen YH; Hsueh PR
    Expert Rev Anti Infect Ther; 2018 Mar; 16(3):205-218. PubMed ID: 29402125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
    MacGowan A; Tomaselli S; Noel A; Bowker K
    J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
    Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.